Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab

Table 1 Baseline characteristics of all three cohorts

	MAX		TRACC		NSWCC cohort
	July 2005 to June 2007		July 2009 to June 2014		Jan 2005 to Dec 2012
	Chemo alone	Chemo + Bev	Chemo alone	Chemo + Bev	Chemo alone	Chemo + Bev
n	33	51	53	126	52	17
Age (yr)
Median	70	67	72	64	66	60
Range	47-84	39-83	31-91	30-87	38-83	21-79
Sex
Male	15	30	22	71	35	11
Female	18	21	31	55	17	6
ECOG
PS 0	14	29	8	45	35	13
PS 1	17	15	28	61	12	3
PS 2	2	7	14	17	5	1
PS 3	NA	NA	3	3	NA	NA
CCI	NA				NA
0			33	89
1-2			14	33
≥ 3			6	4
Primary site
Colon	29	44	48	107	47	15
Rectum	4	7	5	14	5	2
Occult				5
Prior adjuvant Rx
Yes	5	11	10	34	11	4
No	28	40	43	92	41	13
Primary resected
Yes	28	39	24	80	34	16
No	5	12	29	46	18	1
No. of met sites	NA				NA
1			15	30
2			17	45
≥ 3			21	51
Chemo regimen	NA	NA
Single-agent FP			19	12
Oxaliplatin-based doublet			25	87
Irinotecan-based doublet			6	18
Single-agent Irinotecan			0	3
Other			3	6

N/A: Not availiable; Chemo: Chemotherapy; Bev: Bevacizumab.